KR20260007582A - 복소환 화합물 및 그의 용도 - Google Patents
복소환 화합물 및 그의 용도Info
- Publication number
- KR20260007582A KR20260007582A KR1020257037580A KR20257037580A KR20260007582A KR 20260007582 A KR20260007582 A KR 20260007582A KR 1020257037580 A KR1020257037580 A KR 1020257037580A KR 20257037580 A KR20257037580 A KR 20257037580A KR 20260007582 A KR20260007582 A KR 20260007582A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- alkyl
- disorder
- alkoxy
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2023-076322 | 2023-05-02 | ||
| JP2023076322 | 2023-05-02 | ||
| JPJP-P-2024-058286 | 2024-03-29 | ||
| JP2024058286 | 2024-03-29 | ||
| PCT/JP2024/016879 WO2024228399A1 (ja) | 2023-05-02 | 2024-05-02 | 複素環化合物及びその用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20260007582A true KR20260007582A (ko) | 2026-01-14 |
Family
ID=93333055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257037580A Pending KR20260007582A (ko) | 2023-05-02 | 2024-05-02 | 복소환 화합물 및 그의 용도 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4707284A1 (https=) |
| JP (1) | JPWO2024228399A1 (https=) |
| KR (1) | KR20260007582A (https=) |
| CN (1) | CN120958004A (https=) |
| AU (1) | AU2024266462A1 (https=) |
| IL (1) | IL324264A (https=) |
| MX (1) | MX2025013088A (https=) |
| TW (1) | TW202448427A (https=) |
| WO (1) | WO2024228399A1 (https=) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006316052A (ja) | 2005-04-14 | 2006-11-24 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
| WO2013035892A1 (en) | 2011-09-08 | 2013-03-14 | Otsuka Pharmaceutical Co., Ltd. | Piperazine- substituted benzothiophene derivatives as antipsychotic agents |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8431576B2 (en) * | 2009-06-25 | 2013-04-30 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
-
2024
- 2024-05-02 JP JP2025518164A patent/JPWO2024228399A1/ja active Pending
- 2024-05-02 AU AU2024266462A patent/AU2024266462A1/en active Pending
- 2024-05-02 TW TW113116402A patent/TW202448427A/zh unknown
- 2024-05-02 CN CN202480025552.XA patent/CN120958004A/zh active Pending
- 2024-05-02 KR KR1020257037580A patent/KR20260007582A/ko active Pending
- 2024-05-02 EP EP24800130.7A patent/EP4707284A1/en active Pending
- 2024-05-02 WO PCT/JP2024/016879 patent/WO2024228399A1/ja not_active Ceased
-
2025
- 2025-10-27 IL IL324264A patent/IL324264A/en unknown
- 2025-10-31 MX MX2025013088A patent/MX2025013088A/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006316052A (ja) | 2005-04-14 | 2006-11-24 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
| WO2013035892A1 (en) | 2011-09-08 | 2013-03-14 | Otsuka Pharmaceutical Co., Ltd. | Piperazine- substituted benzothiophene derivatives as antipsychotic agents |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202448427A (zh) | 2024-12-16 |
| EP4707284A1 (en) | 2026-03-11 |
| JPWO2024228399A1 (https=) | 2024-11-07 |
| CN120958004A (zh) | 2025-11-14 |
| IL324264A (en) | 2025-12-01 |
| MX2025013088A (es) | 2025-12-01 |
| AU2024266462A1 (en) | 2025-08-28 |
| WO2024228399A1 (ja) | 2024-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019213211B2 (en) | Compounds | |
| AU2018202312B2 (en) | Therapeutic compounds and uses thereof | |
| AU2014216178B2 (en) | Therapeutic compounds and uses thereof | |
| US12018031B2 (en) | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | |
| BR122014012788B1 (pt) | Derivados de pirimidina fundidos, seus usos, e composição farmacêutica para inibição da atividade de tirosina quinase | |
| ES2877627T3 (es) | Compuestos bicíclicos sustituidos | |
| US12435036B2 (en) | Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-n,n-dimethylpropan-2-amine | |
| US20130121963A1 (en) | N-phenyl-2-pyrimidineamine derivatives | |
| EP4153583B1 (en) | 1-((1h-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2h-imidazol-2-one derivatives and related compounds as gpr139 antagonists for the treatment of depression | |
| US11905295B2 (en) | Solid forms of tabernanthalog monofumarate salt for treating neurological disorders and/or psychiatric disorders | |
| KR20260007582A (ko) | 복소환 화합물 및 그의 용도 | |
| US12357623B2 (en) | Method for treating a disease or condition using a pyrazole compound or formulation thereof | |
| CN110753691B (zh) | 用于治疗性和/或预防性治疗癌症的化合物 | |
| JP4176170B2 (ja) | アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬 | |
| HK40129217A (zh) | 杂环化合物及其用途 | |
| KR20130096639A (ko) | 지방산 아미드 하이드롤라제의 조절제 | |
| TW202138371A (zh) | 2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌𠯤-1-基]戊-2-烯腈之固體形式 | |
| US20260124190A1 (en) | Method for treating a disease or condition using a pyrazole compound or formulation thereof | |
| JP2011136991A (ja) | 医薬化合物 | |
| JP2024529984A (ja) | ピリミジン化合物及びその使用 | |
| HK40047992B (zh) | 吡咯并[2 ,3-d]嘧啶化合物的制造方法与中间体及其用途 | |
| JP2021050161A (ja) | 複素環化合物及びその用途 | |
| JPH06157467A (ja) | 3−アザビシクロ[3.2.1]オクタン誘導体およびその用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |